Navigation Links
Biologics Don't Raise Cancer Risk in Rheumatoid Arthritis Patients
Date:10/28/2008

Review finds no connection between drugs that block tumor necrosis factor and malignancies

TUESDAY, Oct. 28 (HealthDay News) -- TNF-antagonists, drugs widely used to treat rheumatoid arthritis (RA), don't appear to cause cancer, say Spanish researchers who analyzed data on more than 4,000 RA patients treated with the biologics.

These drugs, which have been used since 1998 and given to more than 600,000 people worldwide, interfere with biologic substances that cause or worsen inflammation in RA patients. But it's been unclear whether blocking TNF (tumor necrosis factor) increases the risk of cancer, according to background information in an American College of Rheumatology (ACR) news release about the study.

Some studies have suggested an association between RA and certain types of cancer, including lung and blood cancers, but the reasons for this increased risk are uncertain.

The data in this new study came from a drug registry called BIOBADASER, established in 2001 for long-term follow up of the safety of biological therapies in RA patients. The 4,529 RA patients treated with TNF-antagonists were compared with RA patients who didn't receive the drugs.

After they adjusted for age, sex, and RA duration/activity, the researchers found that the rate of cancer in the TNF group was very close to that of the non-TNF group (0.92 percent). Based on this, they concluded that TNF use isn't associated with an increased risk of developing cancer.

"Despite foreseen fears, blocking the tumor necrosis factor does not make patients more prone to develop cancer. All on the contrary, blocking the inflammation cascade may help diminish the overall risk of cancer in these patients," Dr. Loreto Carmona, director of the research unit at the Spanish Foundation of Rheumatology, said in the news release.

The study was presented Monday at the ACR annual meeting, in San Francisco.

More information

The U.S. Agency for Healthcare Research and Quality has more about medicines for rheumatoid arthritis.



-- Robert Preidt



SOURCE: American College of Rheumatology, news release, Oct. 25, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
2. CalbaTech Reports That LifeStems Biologics License Has Been Renewed
3. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
4. Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
5. AstraZeneca - Biologics Day Interviews With Senior Management
6. In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market
7. Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohns Disease
8. Growing Link Between Diabetes and Periodontal Disease Focus of National Gathering for Health Care Leaders
9. Treating your periodontal pockets may benefit your pocket book
10. Ortho Organizers(R) Announces the Launch of the Ancor Pro(TM) Orthodontic Anchorage System Hands-on Course
11. Survey confirms Americans prefer root canal treatment by endodontists
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biologics Don't Raise Cancer Risk in Rheumatoid Arthritis Patients
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
Breaking Medicine Technology: